<div id="readability-page-1"><p>Galapagos NV (NASDAQ:GLPG - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $32.63 and traded as low as $28.27. Galapagos shares last traded at $28.93, with a volume of 249,516 shares changing hands.</p><h2>Analysts Set New Price Targets</h2><p>Several analysts have recently weighed in on the company. Raymond James Financial  reissued a &#34;market perform&#34; rating on shares of Galapagos in a report on Tuesday, February 24th. Weiss Ratings raised Galapagos from a &#34;sell (d)&#34; rating to a &#34;hold (c)&#34; rating in a report on Thursday, February 26th. Wall Street Zen upgraded Galapagos from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 28th. UBS Group  restated a &#34;market perform&#34; rating on shares of Galapagos in a research report on Tuesday, February 24th. Finally, Royal Bank Of Canada boosted their price target on Galapagos from $32.00 to $33.00 and gave the company a &#34;sector perform&#34; rating in a research report on Tuesday, February 24th. One research analyst  has rated the stock with a Strong Buy rating, five have assigned  a Hold rating and one  has given a Sell rating to the company. Based on data from MarketBeat, the stock  has an average rating of &#34;Hold&#34; and a consensus target price of $36.50.</p><p><b>Check Out Our Latest Stock Report on Galapagos</b></p><h2>Galapagos Stock Performance</h2><p>The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -18.43 and a beta of 0.32. The company has a 50-day moving average of $32.61 and a 200-day moving average of $32.63. </p><p>Galapagos (NASDAQ:GLPG - Get Free Report) last issued its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion during the quarter.  As a group, equities research analysts forecast that  Galapagos NV will post -1.6 EPS for the current year. </p><h2>Institutional Trading of Galapagos</h2><p>Several hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC boosted its stake in shares of  Galapagos by 569.0% in the second quarter. EcoR1 Capital LLC now owns 1,036,945 shares of the biotechnology company's stock valued at $29,024,000 after buying an additional 881,939 shares in the last quarter.  Matauro LLC purchased a new stake in shares of  Galapagos in the third quarter valued at approximately $1,647,000.  Norges Bank purchased a new stake in shares of  Galapagos in the second quarter valued at approximately $3,359,000.  Van ECK Associates Corp boosted its stake in shares of  Galapagos by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company's stock valued at $64,000 after buying an additional 750 shares in the last quarter.  Finally, State of Wyoming purchased a new stake in shares of  Galapagos in the second quarter valued at approximately $28,000. 32.46% of the stock is owned by institutional investors and hedge funds. </p><h2>About Galapagos</h2> (Get Free Report)<p>Galapagos NV <span>NASDAQ: GLPG<span></span></span> is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.  </p><p>The company's pipeline encompasses multiple programs across various stages of development.</p><h2>See Also</h2><ul><li>Five stocks we like better than Galapagos</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Galapagos Right Now?</h2><p>Before you consider Galapagos, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.</p><p>While Galapagos currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GLPG

<p>Galapagos NV (NASDAQ:GLPG) shares fell below their 200-day moving average of $32.63, trading at $28.93. Analysts have mixed opinions, with one Strong Buy, five Holds, and one Sell rating. The average target price is $36.50. The company reported $13.92 EPS and $1.06 billion in revenue last quarter. Institutional investors hold 32.46% of the stock. Galapagos focuses on developing small-molecule therapies for chronic diseases and has a market cap of $1.91 billion.</p>

Market Beat

Galapagos NV

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Lakefront Biotherapeutics

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average   - Time to Sell?